<DOC>
	<DOCNO>NCT01131429</DOCNO>
	<brief_summary>Objective : objective study china clarify , whether overall survival different previously untreated stage IIIB/IV lung adenocarcinoma EGFR mutation receive first-line erlotinib plus second-line docetaxel/cisplatin receive first-line docetaxel/cisplatin plus second-line erlotinib .</brief_summary>
	<brief_title>A Chinese Randomized Crossover Study Erlotinib Versus Docetaxel/Cisplatin Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Male female patient age 18 year Histologically proven lung adenocarcinoma clinical stage IIIB/IV ECOG performance status 02 Had prior anticancer agent , radiation surgical therapy lung adenocarcinoma At least one measurable lesion ( accord RECIST ) Provision write informed consent Life expectancy least 12 week History malignant disease . Evidence clinically active interstitial lung disease ( patient chronic , stable , radiographic change asymptomatic need exclude ) Expected life expectancy le 2 month As judged investigator , evidence severe uncontrolled systemic disease ( e.g . unstable uncompensated respiratory , cardiac , hepatic , renal disease ) Aspartate aminotransferase ( AST/SGOT ) alanine aminotransferase ( ALT/SGPT ) ≥ 2.5 x ULN demonstrable liver metastasis ( &gt; 5 x presence liver metastasis ) Evidence significant clinical disorder laboratory find make undesirable subject participate study Pregnancy breastfeed woman ( woman child¬bearing potential ) . Women childbearing potential must practice acceptable method birth control prevent pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>mutation analysis</keyword>
	<keyword>first-line</keyword>
	<keyword>second-line</keyword>
	<keyword>target therapy</keyword>
</DOC>